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The interferon-a (IFN-a) inducing  capacity  of  various  forms  of  immunostimulatory
DNA and the identity of the IFN-a producing cells (IPC) were studied in  human  and
porcine leukocytes. The DNA vaccine vector pcDNA3 induced  production  of IFN-a in
porcine  peripheral  blood  mononuclear  cells  (PBMC),  but  only  if  used  with  the
transfecting agent  lipofectin.  Unmethylated  CpG dinucleotides  in  the  plasmid  were
necessary for induction of IFN-a, but pcDNA3 retained this ability after  mutation  of
the CpG-motifs (5’AACGTT 3’) in the ampicillin  resistance  gene.  Lipofection  and
presence of an unmethylated CpG were also prerequisites  for the ability  of the double
stranded  (ds)  phosphodiester  oligodeoxyribonucleotide  (ODN)  H  (5’
TTTTCAATTCGAAGATGAAT 3’) to activate production of IFN-a in human and porcine
PBMC. Human, but not porcine, PBMC  could  still  produce  high  levels  of  IFN-a in
response  to  certain  single  stranded  (ss)  ODNs,  devoid  of  unmethylated  CpG
dinucleotides. This indicates that there are  species  differences  in  the  recognition  of
immunostimulatory DNA and that eukaryotic  DNA sometimes  can  be  interferogenic.
Certain  CpG-containing  ODNs  with  flanking  poly-G  sequences  were  very  potent
inducers of IFN-a production  in the absence of lipofectin,  both  as phosphorothioate/
phosphodiester  chimeric  ODNs  or  as  phosphodiester  ODNs.  Addition  of  poly-G
sequences  to  the  phosphodiester  ODN  H  clearly  enhanced  its  activity,  but  did  not
replace the need for lipofectin.  The natural  IFN-a producing  cells (NIPC), also termed
plasmacytoid dendritic cells (PDC), were the only cells among human or porcine PBMC
that produced IFN-a in response to immunostimulatory DNA.
The  human  NIPC/PDC  also  produce  IFN-a in  response  to  apoptotic  cells  in
combination  with  autoantibodies  from  patients  with  systemic  lupus  erythematosus
(SLE).  This  activation  was  dependent  on  Fcg-receptor  type  II  (FcgRII),  and  the
NIPC/PDC were shown to express FcgRIIa, but not  the FcgRIIb/c isoforms.  The FcgRIIa
may  also  be  inhibitory,  because  aggregated  IgG  that  binds  FcgR  had  a  general
inhibitory effect on  IFN-a production  induced  by immunostimulatory  DNA or herpes
simplex virus.
Elucidation of the mechanisms whereby NIPC/PDC  are activated  may  result  in  more
efficient vaccine adjuvants and also provide new targets aiming  at  inhibition  of  the
pathologic activation of NIPC/PDC in autoimmune diseases.
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Introduction
General overview of the topic
Deoxyribonucleic acid (DNA), especially DNA  from  microorganisms, has  the
ability to activate the mammalian immune system. The ability to recognize DNA
from pathogens has been interpreted as an innate ability of our immune system to
combat infections. One of the most  rapidly activated defence mechanisms upon
infection is the activation of production of type I interferon (IFN), a cytokine that
inhibits viral replication and regulates ensuing immune responses. The  early
activation of type I IFN is part of the innate immune system (see below) and is
crucial to effectively combat invading microorganisms, but a sustained activation
of the innate immune system may also initiate and maintain an attack on the body
itself.
The  innate  immunity  is  the  first  line  of  defence  against  invading
microorganisms and it is activated irrespectively of whether the pathogen has been
encountered before or not. The  adaptive immune  response acts  via  molecules
(antibodies and T-cell receptors) that specifically interact with structures of the
invading  microorganisms,  and  the  pathogen  is  therefore  more  efficiently
eliminated. This adaptive immunity to microorganisms  is  often  long  lived,
forming the basis of an immunological memory. Upon  re-encountering of  the
pathogen, the adaptive immune response is therefore more rapidly activated and
the clearance of the  pathogen is  more  effective, preventing or  mitigating  the
disease. The ability to elicit a specific immunological memory is  an important
property of vaccines against microorganisms.
The  innate  immune  system  roughly  includes  the  skin,  mucosal  surfaces,
phagocytes, natural killer (NK) cells, antigen presenting cells (APC), complement
factors, chemokines, cytokines and acute phase proteins. Together, they restrain
the spread of invading pathogens by a number of mechanisms, including ingestion
or lysis of pathogens or direct inhibition of their replication. The type  I  IFN
participates in these events by binding to the type I IFN receptor, which rapidly
activates transcription factors that induce transcription of a number of molecules
with direct antiviral effects. The production of type I IFN can  be  induced by
bacteria, virus and molecules derived from them,  e.g.  lipopolysaccharide (LPS),
glycoproteins, double stranded (ds) ribonucleic acid (RNA) and certain so  called
immunostimulatory DNA (IS-DNA) sequences. These type I IFN inducers activate
transcription factors that then translocate to the nucleus and bind to promoters of
type I IFN genes, thereby activating their transcription. Most cell types have the
ability  to  produce  type  I  IFN,  but  a  distinct  cell  type  termed  natural  IFN
producing cell (NIPC) or plasmacytoid dendritic cell (PDC) has the ability  to
rapidly produce very high levels of type I IFN. The type I IFN and other cytokines
produced by NIPC/PDC and other cells of the innate immune system,  such as
macrophages and dendritic cells (DC), can stimulate the development of efficient
adaptive immunity in many ways. Therefore, the cytokines  and  the  cells  that
produce them can be thought of as the link between innate and adaptive immunity.
The present thesis focuses on the type  I  IFN  inducing  capacity of  molecules10
containing  immunostimulatory  nucleic  acids  derived  from  microorganisms
(exogenous) or eukaryotic host cells (endogenous), and the cells that produce type
I IFN in humans and pigs.
The type I IFN system
Type I IFN genes and proteins
The type I IFNs are immunoregulatory proteins that are unique among cytokines
in that many of them both have direct antiviral effects and the ability to activate
cells of the immune system. In man,  the type I IFNs comprise IFN-a, IFN-b,
IFN-w, IFN-e and IFN-k (Samuel, 2001), and lately a type I IFN related protein
named  IFN-l  was  found  (Kotenko et al., 2003). Interestingly, there  are  13
different  subtypes  of  IFN-a in man. In pigs, the type I IFNs include  IFN-a,
IFN-b and IFN-w but also a novel type I IFN called trophoblastic IFN (IFN-d) (La
Bonnardière, Lefèvre & Charley, 1994). Pigs have about 12 IFN-a and 3 IFN-w
subtypes. In both human and pigs, the type II IFN is represented by IFN-g, which
is involved in both the innate and adaptive immune response (Farrar & Schreiber,
1993). The roles of IFN-a and IFN-b in the immune system are by far the most
studied among the type I IFNs and the term type I IFN will  hereafter refer to
IFN-a and IFN-b only. All type I IFNs seem to act through the same receptor,
IFNAR,  that  has  two  subunits,  IFNAR1  and  IFNAR2  (Novick,  Cohen  &
Rubinstein, 1994; Uzé, Lutfalla & Mogensen, 1995). The receptor is anchored in
the cell membrane from where it transduces signals upon activation, but a soluble
form may also exist that regulates the active levels of type I IFN (Hardy et al.,
2001).
The multiplicity of the IFN-a genes may be a result of the need to produce large
amounts of especially IFN-a from a small number of cells in  a short period of
time. All type I IFNs are encoded by intronless genes, which may facilitate the
process of transcription and translation. However, during the course of evolution,
the type I IFN genes have undergone much diversification, which is indicative of a
selective pressure favoring different functions. The function of human IFN-a7 is
for instance different from many other subtypes in that it cannot activate NK-cells
(Ortaldo et al., 1984). Furthermore, although IFN-b and all IFN-a subtypes act
through the same receptor,  IFNAR,  the  latter  can  mediate  different signals
dependent on the activating type I IFN (Brierley & Fish, 2002).
Activation and regulation of type I IFN gene expression
The spectrum of type I IFN inducers includes virus, bacteria and components of
microorganisms such as glycoproteins, LPS, dsRNA and IS-DNA. The inducers
also include immune complexes (IC) containing  nucleic  acids  and  synthetic
inducers  such  as  imiquimod,  the  dsRNA  analogue  poly  I:C  and
oligodeoxyribonucleotides (ODN) containing  unmethylated  CpG  dinucleotides
(CpG-ODN) (Fitzgerald-Bocarsly, 2002). Depending on the nature of the  IFN-
inducer, different regulating mechanisms are in play. Specific receptors responsible
for the activation of type I IFN by whole viral particles or bacteria are not known,
but recently the Toll-like receptors (TLR) have been shown to mediate expression11
of  type  I  IFN  induced  by  poly  I:C,  LPS,  imiquimod  and  DNA  containing
unmethylated CpG dinucleotides (CpG-DNA). TLRs are receptors that recognize
pathogen associated molecular patterns (PAMP), but also host-derived ligands that
are indicative of infection, such as the heat-shock proteins (Takeda, Kaisho  &
Akira, 2003). Upon triggering of TLR, signalling pathways leading to  cytokine
production are activated (see below).
The multiplicity of type I IFN genes is also reflected in that different cell types
and /or tissues express unique patterns of type I IFN.  The different expression
levels of individual IFN-a mRNA transcripts in different cell types is regulated at
the transcriptional level. The explanation for this  can either be found in  single
mutations within the promoter and/or the presence of negative regulatory domains
(Pitha &  Au,  1995).  The  expression is  regulated by  different repressors and
activators of transcription that compete for binding to the type I IFN promoters
(Hiscott, Nguyen & Lin, 1995). For example, in a non-induced cell, the  IFN
regulatory factor (IRF)-2 is tightly bound to the IFN-b promoter, which prevents
leakage. Upon activation, IRF-2 and other transcriptional repressors are replaced by
activating IRFs and NFkB that bind to the positive regulatory domains (PRD) of
the IFN-b promoter. A tight regulation of IFN-b production is  achieved by  a
feedback loop where new synthesis of the repressor IRF-2 is activated by  type I
IFN.  In  the  early  phase  of  a  virus-mediated  activation  of  IFN-a/b, the
amplification signal is enhanced by the activation of several IRFs, which allows
transcription of many different subtypes of IFN-a (Barnes, Lubyova &  Pitha,
2002;  Servant,  Tenoever  &  Lin,  2002).  For  example,  virus-induced
phosphorylation of the constitutively expressed IRF-3 will allow its translocation
to the  nucleus where it  can activate transcription by  binding  to  PRDIII of the
IFN-b promoter and to the corresponding sequence in the virus response element
of distinct IFN-a promoters. Secreted IFN-b and IFN-a will in turn activate new
synthesis of IRF-5 and IRF-7, which together with IRF-3 activate a much broader
spectrum of IFN-a subtypes. Furthermore, more cells will be activated to produce
type I IFN, because the IFN produced from the initial activation turn on IRF
transcription in other cells, which then become more proficient producers of IFN.
These amplifying mechanisms will allow a prompt and massive production of
many different subtypes of type I IFN. Recently, the two kinases TBK1 and IKKe
which have been linked to the TLR pathway (Barton & Medzhitov, 2003), have
been shown to activate IRF-3 and IRF-7 (Fitzgerald et al., 2003; Sharma et al.,
2003) (see below).
Because the transcription factors regulating the initial type I IFN expression are
constitutively expressed and activated by post-translational modification, the IFN-
response is rapidly initiated. This allows efficient inhibition of the replication of
microorganisms, especially viruses.
Effects of type I IFN
Antimicrobial effects of type I IFN
In general, a virus depends on the cellular machinery of its  host  to  replicate its
genome and to synthesize new viral proteins and finally to assemble viral progeny.
The type I IFNs interfere with many steps in  this  infectious cycle,  including12
transcription, translation, and by activating apoptosis in infected cells. There are
several signalling pathways that are activated upon binding of type I IFN to  the
IFNAR. Constitutively expressed Jak1/Tyk2 tyrosine kinases are always bound to
the cytoplasmic part of the receptor. When the receptor is triggered by its ligand,
these kinases are activated, leading to the further activation of the signal transducer
and activator of transcription (Stat) 1 and Stat2 proteins (Brierley & Fish,  2002).
Activated Stats can form many different transcription factor complexes, e.g.,  by
forming hetero- or homodimers with other Stat molecules or by interactions with
other proteins. One of the best studied transcription factor complexes activated by
type I IFN is the IFN stimulated gene factor 3 (ISGF3) that is composed of Stat1,
Stat2  and  IRF-9.  ISGF3  recognizes the  conserved IFN  stimulated  response
element (ISRE) present in the promoters of many IFN stimulated genes (ISG).
Other Stat-containing transcription factors activated by type I IFN recognize the
gamma-activated  sequences  present  in  many  ISGs  (Brierley  &  Fish,  2002;
Samuel, 2001)
Among  the  most  important  IFN-inducible  antiviral  molecules  are  the
dsRNA-dependent protein kinase (PKR), 2’, 5’ oligoadenylate synthetase (OAS)
and the Myxovirus  resistance (Mx)  protein  (Brierley &  Fish,  2002;  Samuel,
2001). The expression of these molecules is regulated by transcription factors that
bind to ISRE in their promoters. Both PKR and OAS expression is induced by
type I IFN, but the enzymatic activity is activated by the viral product dsRNA.
This dual regulation of expression and subsequent activation is  indicative of a
control mechanism assuring activity only when it is required. Activated OAS will
catalyze the formation of 2’-5’ linked ATP  molecules of varying length.  These
oligomers will in turn activate RNaseL, which in a dimerized form cleaves single
stranded (ss) RNA, thereby preventing translation. Binding  of dsRNA to  PKR
will induce a conformational change that activates the catalytic domain of PKR.
Activated PKR will inhibit the eukaryotic initiation of translation factor (eIF2a)
and thereby prevent translation of  mRNA  to  protein.  In  general, the  defence
against viruses rarely depends on one single mechanism, but  rather on  many in
concert that will interfere with viral replication. An illustrating example of this is
the type I IFN-activated Mx proteins that can interfere with many different stages
of viral replication, e.g. by disrupting viral RNA  polymerase, sequestering of
ribonucleoproteins or inhibition of nuclear export of viral RNA,  to  name a few
(Haller & Kochs, 2002). The individual and collective effects of the ISGs PKR,
OAS and Mx protein are however not  the only  antiviral systems because mice
devoid of all three genes still have some type I IFN-inducible antiviral activity
(Brierley & Fish, 2002).
Type I IFN can also activate functions of cells that are important in both innate
and adaptive immunity against bacteria (see below). While the importance of type
I IFN in antiviral immunity is well established, the physiological role of type I
IFN in the defence against bacteria is less explored.
Antiproliferative, apoptotic and immunological effects of type I IFN
Apart from directly interfering with viral  replication,  the  vertebrate immune
system has also evolved mechanisms to kill infected cells, thereby eliminating the13
whole machinery on which viral replication relies. For instance, the IFN-inducible,
dsRNA-activated enzymes PKR (Balachandran et al., 1998) and OAS (Ghosh et
al., 2001) can activate apoptosis in infected cells. Type I IFN will also enhance
killing of infected cells by up-regulation of  major  histocompatibility  complex
(MHC) class I that is recognized by cytotoxic T (Tc) cells (Belardelli & Ferrantini,
2002) and by enhancing the cytotoxic effect of NK-cells (Biron et al., 1999).
Furthermore, type I IFN can affect every step in the cell  cycle  by  indirect
inhibition of cyklin-dependent kinases, enzymes necessary for the transition of a
cell cycle step to another (Brierley & Fish, 2002). A possible role for the anti-
proliferative effect of type I IFN is in the control of hematopoetic neoplasms.
The immunological aspects of type I IFN  effects on  host  cells  include  the
regulation of DC, helper T (Th) cells, B-cells and Tc cells. The activation of naive
T-cells requires presentation of antigenic peptides complexed to  MHC  on  the
surface of APC. Effective APC are often DC  that have matured from precursor
cells. Presentation of antigen by immature DC that lack co-stimulatory molecules
can lead to T-cell anergy and tolerance to the antigen in question. Furthermore, in
the absence of the correct chemokine receptor expression, the immature APC  are
incapable of homing to the lymphoid organs where the T-cells reside. Type I IFNs
have important functions on the maturation of DC (Penna et al., 2002; Santini et
al.,  2002).  For  instance,  immature  DC  will  upregulate  their  expression  of
chemokine receptors, e.g., CCR7 in  the  presence of IFN-a. This  makes  DC
responsive to chemokines such as MIP3-b and allows homing of activated DC to
the T-cell areas of lymphoid organs. The effects of type I IFN on immature DC
also  include  up-regulation  of  co-stimulatory  molecules  such  as  cluster  of
differentiation (CD) 86, CD80 and CD40 that will  ensure activation of T-cells.
Also, maturation of DC is associated with upregulation of both MHC class I and
MHC class II (Montoya et al., 2002; Santini et al., 2002), which further increases
the antigen presenting ability of DC.
Apart from facilitating activation of Th cells by activated APC, type I IFN in
concert with interleukin-12 (IL-12) can promote the development of type 1  Th
(Th1) cells (Cella et al., 2000; Krug et al., 2001a). The cytokines produced by
Th1 cells, e.g. IFN-g and tumor necrosis factor-b (TNF-b), stimulate strong cell-
mediated immunity and production of effective opsonizing and complement-fixing
IgG antibodies. In  contrast,  type  2  Th  (Th2)  cells  produce e.g.  IL-4,  which
stimulates production of IgE antibodies that are associated with  atopic reactions
and helminth infections. Th2 cells also produce cytokines that can down-regulate
cell-mediated  immunity,  e.g.  IL-10.  T-cells  are  also  affected  by  the  anti-
proliferative effects of type I IFN (see above), dependent on their activation state
(Marrack, Kappler & Mitchell, 1999). For  instance,  the  proliferation of  naive
T-cells is prevented by IFN-a, whereas activated T-cells can divide even in  the
presence of IFN-a (Dondi et al., 2003). This may represent a control mechanism
to assure the expansion of antigen-specific T-cell clones.
An efficient adaptive immune response against microbial  infections includes
production of antibody classes and subclasses with  distinct  effector mechanisms
that contribute to the eradication of the pathogen (Butler & Howard,  2002;
Crawley  &  Wilkie,  2003).  For  instance,  certain  IgG  subclasses  activate14
complement and bind with high affinity to Fc-receptors (FcR), both enhancing for
instance phagocytosis of pathogens by macrophages. Type I  IFNs  promote  Ig
class-switching in B-cells in several ways. It has thus been demonstrated that type
I IFN can induce differentiation of Th1 cells, which promotes class-switching to
IgG2a in mice (Sinigaglia, D'Ambrosio & Rogge, 1999). Furthermore, it has also
been demonstrated that DC exposed to type I IFN enhance antibody production in
general and class-switching in B-cells (Le Bon et al., 2001). Such DC can in fact
directly induce class switching in B-cells, independently of T-cells (Litinskiy et
al., 2002). Apart from affecting the antibody production in  B-cells, type I IFN
also promotes survival and differentiation of B-cells (Ruuth et al., 2001)  and
enhances  B-cell  receptor  dependent  responses  by  lowering  the  threshold  of
activation (Braun, Caramalho & Demengeot, 2002).
Type I IFN also stimulates the development of Tc cells. For  instance, type I
IFN caused the development of Tc cells from naive CD8+  T-cells via induced
expression of the chemokine IP-10 and its  receptor CXCR3  (Ogasawara et al.,
2002). Furthermore, type I IFN can stimulate proliferation of memory Tc cells via
induction of the cytokine IL-15 (Sprent et al., 1999).
The capacity of type I IFN to activate both accessory immune cells, such as DC,
and effector cells, such as B- and T-cells, is  beneficial in  combating infections.
However, sustained and prolonged activation of type I IFN or treatment of virus
infections or tumors with IFN-a can also cause development of autoantibodies and
autoimmune disease (Ioannou &  Isenberg, 2000;  Raanani &  Ben-Bassat, 2002;
Rönnblom & Alm, 2003). In fact, type I IFN may be an important pathogenic
factor in certain autoimmune diseases, as will be discussed below.
The cells producing type I IFN
In humans many different  cell  types  can  produce type  I  IFN  in  response to
microbial stimuli. Fibroblasts produce mainly IFN-b, whereas leukocytes are the
major source of IFN-a. Among leukocytes, the NIPC/PDC,  monocytes and to
some extent myeloid  DC  are the  main  producers of  type  I  IFN.  Monocytes
producing  IFN-a  constitute  approximately  1  cell  per  100  peripheral  blood
mononuclear cells (PBMC) and produce 0.1-0.2 antiviral units (U) IFN per cell in
response to certain RNA viruses, such as Sendai virus (SV), but cannot produce
IFN-a to most other types of virus or other type I  IFN  inducers (Fitzgerald-
Bocarsly, 1993, 2002; Gobl, Funa & Alm, 1988).  The  myeloid  DC  produce
intermediate  levels  of  IFN-a in response to the  dsRNA  analogue  poly  I:C
(Kadowaki, Antonenko & Liu, 2001). The NIPC constitute only 1-2 cells per
1000 PBMC but produce 1-2 U IFN per cell in response to a broad spectrum of
inducers  including  herpes  simplex  virus  (HSV),  SV  (Feldman et al.,  1994;
Fitzgerald-Bocarsly, 1993, 2002), bacteria (Funa et al., 1985;  Svensson et al.,
1996a) and also parasites (Rönnblom et al., 1983). The NIPC/PDC were initially
defined as null lymphocytes, because they lacked specific lineage markers for T-
cells, B-cells, NK-cells and monocytes (reviewed in Fitzgerald-Bocarsly, 1993,
2002). Further analysis of the HSV-stimulated NIPC  revealed that they express
e.g. MHC class II, CD4, CD36, CD40, CD83, CD72 and CD45RA but not CD5,
CD80,  CD86,  CD11b  or  CD11c  (Svensson et al., 1996b).  This  phenotype15
suggested that the NIPC corresponded to previously described immature DC
(O'Doherty et al., 1994). Further characterization of such immature DC in blood
revealed that they were precursors of DC with a unique phenotype and morphology
(Grouard et al., 1997; Olweus et al., 1997) and they were termed plasmacytoid
monocytes/T-cells. Functional analysis of their antigen-presenting ability showed
that they preferentially promote Th2 cell development and  they  were therefore
named  precursors  of  type  2  DC  (Rissoan et al., 1999), but  are  now  more
commonly termed plasmacytoid DC (PDC). When it was shown that the PDC had
the same ability  to  produce IFN-a as the NIPC,  and had a similar phenotype
(Cella et al., 1999; Siegal et al., 1999), the cellular identity of these cells merged
and they are now sometimes referred to as NIPC/PDC. Another characteristic of
these cells is their high expression of the IL-3 receptor (CD123),  which  is
important for IL-3 induced survival and maturation (Grouard et al., 1997; Rissoan
et al., 1999).
The blood dendritic cell antigen (BDCA) molecules 2 and 4 are  also  rather
selectively expressed by NIPC/PDC, which have facilitated  their  purification
(Dzionek et al., 2000). The BDCA-2 is a type II C-type lectin that can capture and
internalize antigens and the BDCA-4 appears important in the interaction between
DC and T-cells (Dzionek et al., 2002), but their importance for special functions
in  NIPC/PDC  remains  to  be  elucidated.  Interestingly,  however,  binding  of
antibody to BDCA-2 can down-regulate production of IFN-a (Blomberg et al.,
2003;  Dzionek et al., 2002).  In  addition,  the  NIPC/PDC  express chemokine
receptors such as CXCR3, CXCR4 and CCR5 that are important in recruiting DC
to  lymphoid  organs.  For  instance,  in  the  presence of  the  chemokine  SDF-
1/CXCL12 that interacts  with  CXCR4,  the  NIPC/PDC  migrate  to  secondary
lymphoid organs (Penna et al., 2002). The NIPC/PDC also express TLR1, 6, 7, 9
and 10 (Hornung et al., 2002), receptors involved in the recognition and response
to microbial products such as CpG-DNA (see below). The Fcg-receptor (FcgR)
type II (FcgRII/CD32) may also be expressed on these cells (Olweus et al., 1997)
but subsequent phenotyping of NIPC/PDC  have  failed to  detect this  receptor
(Dzionek et al., 2000; Svensson et al., 1996b). Furthermore, the NIPC/PDC also
express low levels of the mannose receptor, which is involved in scavenging and
possibly also  HSV-mediated activation of  type  I  IFN  production (Fitzgerald-
Bocarsly, 2002).
The human NIPC/PDC have a unique ability to produce large amounts of type I
IFN, but they are also capable of producing IL-12 if stimulated in the presence of
CD40 ligand (Krug et al., 2001b). Other cytokines produced by these cells are IL-
6 and TNF-a (Fitzgerald-Bocarsly, 2002) and the chemokines IL-8, IP-10 (Krug et
al., 2001b), CCL3/MIP-1a and CCL4/MIP-1b (Penna et al., 2002). Considering
the wide range of agents that activate NIPC/PDC and the spectrum of cytokines
they produce, the  NIPC/PDC  are likely  to  have  an  important  activatory and
regulatory role in the immune system.
Cells that correspond to the human NIPC/PDC and  produce high  levels  of
IFN-a in response to virus have also been identified in mice (Asselin-Paturel et
al., 2001; Nakano, Yanagita & Gunn, 2001). The murine NIPC/PDC differ from
the human counterpart (Hochrein, O'Keeffe & Wagner, 2002) in that they express16
CD11c, can express CD8 but do not express CD123 (IL-3R). In contrast, spleen
IPC  activated  by  HSV  were  localized  in  the  marginal  zones  and  had  a
heterogenous expression of metallophilic and marginal zone macrophage markers,
lacked surface markers for T-cells and B-cells, but also MHC class II and CD11c
(Eloranta & Alm, 1999). These  cells  therefore clearly differ from  the  murine
NIPC/PDC.
In  pigs,  blood  leukocytes  that  produce  IFN-a after  stimulation  with  the
coronavirus transmissible gastroenteritis  virus  (TGEV)  (Nowacki  &  Charley,
1993) or Aujeszky’s disease virus  (ADV) (Artursson et  al., 1995)  have  been
characterized. The porcine cells producing  IFN-a in  response  to  TGEV  are
approximately 1-2 in 10,000 PBMC, lack markers for T-cells and B-cells and
express MHC class II and CD4 (Charley & Lavenant, 1990; Nowacki & Charley,
1993). Furthermore, purification of porcine blood cells expressing the myeloid
marker SWC3 revealed that a subpopulation of these cells that expressed CD4 and
MHC class II, but not markers for T-cells, B-cells or monocytes, were the only
cells capable of producing IFN-a in response to TGEV (A. Summerfield, personal
communication). In vivo, IPC have been found in  porcine lymph  nodes  after
intradermal administration of ADV-infected  cells  (Artursson et  al.,  1995).
Phenotypical  analysis  of  porcine  IPC  localized  in  lymphoid  tissues  after
stimulation with TGEV showed that these cells phenotypically resemble  the
TGEV-activated cells in porcine blood cultures  and  that  they  expressed the
myeloid marker SWC3 (Riffault et al., 1997; Riffault et al., 2001). Although the
frequency of the porcine cells producing IFN-a in response to coronavirus is lower
than  the  frequency  of  HSV-stimulated  human  NIPC,  the  two  cell  types
phenotypically resemble each other. Important cell surface molecules expressed on
human/porcine NIPC/PDC and cytokines produced by these cells as well as
principal activating agents are illustrated in Figure 1.
Immunostimulatory DNA
When Yamamoto et  al  investigated the  active component in  a  mycobacterial
extract with potent anti-tumor activity, they found that  neither the  RNA,  nor
protein content, but instead the DNA content could  confer anti-tumor  activity
(Yamamoto et al., 2002). Short ODNs containing sequences from mycobacteria,
especially those containing a hexameric palindrome with a 5’ CpG 3’ dinucleotide,
could mimic the effect of the bacterial extracts. Since this discovery, it has been
demonstrated that bacterial DNA or ODNs have many  effects on  the  immune
system that is dependent on the  presence of  unmethylated CpG  dinucleotides
(Krieg, 2002). Interestingly, CpG dinucleotides normally occur at the expected
frequency in bacterial DNA, 1 in 16 nucleotides, but  are much less frequent in
eukaryotic DNA. Whereas the CpGs of bacterial DNA are mostly  unmethylated,
the CpGs in eukaryotic DNA are frequently methylated on the cytosine (Bird,
1987;  Tweedie et al., 1997). Due to this difference, the ability to react  to
unmethylated CpG has been interpreted as an innate ability to detect foreign DNA.
Such CpG-motifs have been  identified  in  many  bacterial plasmids  that  are
employed in DNA vaccination, which may explain their adjuvant potential (Tighe
et al., 1998) (see below). Since the initial discovery of IS-DNA it has been shown17
that IS-DNA, and many  other  bacterial and  viral  constituents,  activate innate
immunity through pattern recognition receptors (PRR) that are present on cells of
the immune system (Akira & Hemmi, 2003). The effects of IS-DNA on the host
immune system include activation of  B-cell  proliferation and  production  of
cytokines that will potentiate the antigen-presenting function of macrophages and
DC and favor the development of Th1 cells (Krieg, 2002). Because of this
enhancement of immune responses, IS-DNA is considered an effective adjuvant in
vaccine formulations (see below).
Sequence specificity and chemical modification of IS-DNA
The initial analysis of IS-DNA established the concept of a palindromic hexameric
sequence with at least one CpG dinucleotide as the optimal motif in an ODN for
activation  of  NK-cells  and  production  of  IFN  (Yamamoto  et  al.,  1992a;
Yamamoto et al., 1992b; Yamamoto, Yamamoto & Tokunaga,  2000).  It  was
further demonstrated that the bases surrounding the CpG  dinucleotide were of
importance for the activity. The CpG dinucleotide plus one or two bases on the 5’
and 3’ side are termed a CpG  motif.  For  instance, the optimal  CpG-motif for
murine B-cell stimulation is 5’ purpurCpGpyrpyr 3’ (Krieg et al., 1995). Since
then, it has been shown that the optimal CpG-motif  may  differ both  for  the
parameter studied  (Krieg,  2002),  and  between  species  (Bauer et  al.,  2001;
Takeshita et al., 2001). In pigs, among several motifs tested, the CpG-motif 5’
ATCGAT 3’ was most efficient for induction of IL-6, IL-12, TNF-a and blood
leukocyte proliferation (Kamstrup, Verthelyi & Klinman, 2001). Furthermore, the
CpG  motif  5’  GACGTT  3’  also  efficiently  induced  proliferation  of  blood
leukocytes in several veterinary species including pigs, whereas in mice and
rabbits, the CpG-motif 5’ GACGTT 3’ was the strongest inducer (Rankin et al.,
2001). Although the concept of an unmethylated CpG dinucleotide as a basis for
immune  stimulation  by  DNA  holds  true  in  most  situations,  introduction  of
vertebrate dsDNA without a CpG motif into cells can activate Stat1,  Stat2  and
MHC gene expression (Suzuki et al., 1999). In addition, not all CpG-motifs are
activatory and some can actually inhibit  the  stimulatory  effects of  CpG-DNA
(Krieg, 2002), which has been interpreted as a  mechanism whereby pathogens
prevent activation of the vertebrate immune system (Hasslung et al., 2003; Krieg
et al., 1998). Furthermore, DNA sequences without CpG dinucleotides can also
have a suppressive effect on immune activation (Zeuner et al., 2003).
The immunostimulatory activity of CpG-DNA in the form  of  ODN  can  be
altered by using phosphorothioate  instead  of  phosphodiester nucleotides. This
increases the resistance  to  nucleases  and  thereby  protects  the  ODN  from
degradation (Krieg, 2002). In a phosphorothioate-stabilized nucleotide, one of the
non-bridging  oxygens  of  the  phosphate  group  is  converted  to  sulphur.
Phosphorothioate ODNs are 200 times more efficient than phosphodiester ODNs
at B-cell activation (Krieg et al., 1995) and they are more efficiently taken up by
cells (Zhao et al., 1993). The potency of a given CpG-motif may differ between
the two forms and the phosphorothioate form has intrinsic non-sequence specific
biological activity (Krieg, 2002). Another way to improve the efficacy of an ODN
is to add poly-G sequences in the 5’ and/or 3’ ends, which is thought to facilitate18
uptake, possibly by binding to scavenger receptors (Kimura et al., 1994;  Lee et
al., 2000; Pearson, Rich & Krieger, 1993; Pisetsky, 1996).
Mechanisms involved in the activation by IS-DNA
In contrast to free CpG-DNA molecules, immobilized CpG-DNA cannot activate
lymphocytes (Krieg et al., 1995; Manzel &  Macfarlane, 1999), which indicates
that cell uptake is necessary. After uptake, CpG-DNA appears to locate to the
endosomal compartment (Krieg, 2002). Treatment with bafilomycin A, monensin
or chloroquine completely block CpG-signalling, which indicate that maturation
and/or acidification of the endosomal compartment is  a  prerequisite for  CpG-
mediated activation of immune cells (Häcker et al., 1998; Yi et al., 1998). Many
DNA-binding cell surface proteins have  been  found,  but  still  no  one  with
specificity for immunostimulatory sequences. A non-specific entry mechanism for
CpG-DNA  is  supported  by  the  findings  that  CpG-ODN  and  non-CpG-ODN
equally well bind to cell membranes (Häcker et al., 1998; Krieg et al., 1995) and
are incorporated into cells (Ahmad-Nejad et al., 2002), and that  an  excess of
non-CpG-ODN can abrogate the activity of CpG-ODN (Häcker et al., 1998). The
acidification that is  required for  signalling  has  however been  associated with
increased binding of CpG-ODN, but not of non-CpG-ODN, to cells (Hu, Sun &
Zhou, 2003). Also, upregulation of TLR9, the receptor mediating CpG-signalling
(see below), also increases the specific uptake of CpG-ODN (Takeshita et  al.,
2001).
The role of TLR9 in activation by CpG was first shown using TLR9 knock-out
mice that could not respond to CpG-DNA, but had unaltered responses to  other
PAMPs, such as LPS (Hemmi et al., 2000). In human cells, transfection of non-
TLR9 expressing cells with TLR9 confers responsiveness to CpG-DNA (Bauer et
al., 2001; Takeshita et al., 2001), which demonstrates that TLR9 is involved in
cellular activation by  CpG-ODN in  human  cells. The  TLR  family,  initially
identified in Drosophila, is  PRRs  that confer responsiveness to  many different
conserved pathogen-associated molecules, synthetic compounds and endogenously
derived ligands (Akira & Hemmi, 2003).  The  signalling  pathways leading  to
altered gene transcription after triggering of a TLR are well worked out (Akira &
Hemmi, 2003). For instance, activation of TLR will activate both NFkB and
MAPK signalling pathways. Moreover, activation of NFkB-dependent genes by
CpG-DNA has  been  shown  to  occur via  activation of  the  PI3  kinase  DNA-
dependent  protein  kinase  (DNA-PK)  (Chu et al., 2000). If and how signals
activated by TLR9 and DNA-PK converge remains to  be elucidated (Aderem &
Hume, 2000), but recently the  involvement  of  DNA-PK has  been  questioned
(Hemmi et al., 2003), possibly favoring the involvement of another PI3 kinase in
CpG-mediated activation of immune cells (Ishii et al., 2002).
Final proof of TLR9-mediated activation of type I IFN by CpG in human cells
is still missing. Nevertheless, the ability to produce IFN-a in response to CpG-
DNA correlates well with expression of TLR9 (Krug et al., 2001b). The MAPK
pathway known to be activated by TLR ligands, is involved in the CpG-mediated
activation of Stat1, that independently of type I IFN signalling activates ISGF3,
which initiates transcription of IRF7, thereby contributing to the induction of type19
I IFN by CpG-DNA (Takauji et al., 2002). The mechanisms that link activation of
TLR9 and the activation of type I IFN genes remain to  be identified. However,
two kinases, IKKe and TBK1, that are likely triggered by TLR were  recently
shown to activate the type I IFN transcription factors IRF3 and IRF7 (Fitzgerald et
al.,  2003;  Sharma et al., 2003).  Further  studies  will  tell  if  this  pathway is
involved in the activation of type I IFN by CpG-DNA.
In humans, TLR9 is mainly expressed on B-cells and NIPC/PDC (Krieg, 2002).
Some of the immunostimulatory effects of CpG-DNA are therefore direct effects
due to the activation of these cells, but many  are indirectly mediated by  the
cytokines, including type I IFN, produced by the TLR9-bearing NIPC/PDC (see
above). In this way, the human NIPC/PDC are key cells in mediating the effects
of CpG-DNA on the immune system. The situation may be somewhat different in
mice where TLR9 expression is not limited to NIPC/PDC and B-cells. Little is
known of the relevant expression of TLR9 in pigs (Shimosato et al., 2003).
Use of IS-DNA in DNA vaccination
In  general,  an  effective  vaccine  should  activate  both  humoral  and  cellular
immunity  to  the  antigen  in  question,  preferentially  with  a  Th1  profile  that
includes efficient antibodies and Tc  cells.  Tc  cells  are activated by  antigenic
peptides in the context of MHC class I, which generally requires that the protein is
synthesized in or introduced to the cytoplasm. On the other hand, Th  cells are
activated by peptides presented  in  the  context  of  MHC  class  II  on  APC.
Dependent on the cytokines produced by APC, including NIPC/PDC, Th1 or Th2
cells develop. The principle of  immunization  with  DNA  vaccines is  that  the
antigen is delivered as a gene that will be expressed within the cytoplasm of the
host cell. The antigen can therefore theoretically be presented on MHC class I, but
also on MHC class II by APC that have endocytosed secreted antigen. In this way,
DNA vaccination may provide a tool  to  effectively activate both  cellular and
humoral responses to delivered antigens as (reviewed in Srivastava & Liu, 2003).
Unlike purified protein antigens,  infectious  agents  typically  induce  strong
immune responses without the addition of adjuvants. An adjuvant, be it a separate
molecule  or  an  innate  property  of  the  antigen  itself,  will  increase  the
immunogenicity of an antigen. There are many steps in the immunization process
that are  subject  to  improvement by  adjuvants,  including  activation of  innate
immunity (Lövgren-Bengtsson & Fossum, 2002; Schijns, 2002). In the absence
of adjuvants activating innate immunity, presentation of antigen may lead to Th2
development or tolerance to  the  antigen.  Due  to  CpG-motifs  in  the  plasmid
backbone,  DNA  vaccines  often  have  an  intrinsic  ability  to  activate  innate
immunity, resulting in production of cytokines and upregulation of costimulatory
molecules on antigen-presenting DC. Cytokines, including type I IFNs,  play an
important role in this activation (Cull et al., 2002; Rizza et al., 2002; Tudor et
al., 2001).
Adjuvant IS-DNA can be used in several forms. A CpG-containing ODN can be
used  either  in  phosphodiester  or  phosphorothioate  form  (see  above)  and
administered neat or encapsulated in liposomes, free or covalently linked to  the20
antigen (Krieg & Davis, 2001). At present, a limited number of studies have been
performed in the pig, where CpG-ODNs were used as adjuvants in vaccines (Alcón
et al., 2003; Van der Stede et al., 2002). Although many different formulations of
antigen and DNA-based adjuvants have been tested, it is  difficult to  predict the
immunological result of a given formulation, but the increasing knowledge of the
molecular mechanisms involved will facilitate the design of new vaccines.
IFN-a inducing immune complexes and autoimmune disease
The type I IFN system may have an etiopathogenic role in  the development of
autoimmune disorders, such as systemic lupus erythematosus (SLE) (reviewed in
(Rönnblom & Alm, 2003). Patients with the autoimmune rheumatic disease SLE
often have an  ongoing  production of  IFN-a, which  in  addition  correlates to
disease activity. Furthermore, treatment of patients with tumors or viral infections
with  IFN-a  can  give  rise  to  autoantibodies  and  occasionally  SLE.  An
etiopathogenic  role  of  IFN-a in  SLE  is  further  suggested  by  the  many
immunomodulatory effects of this cytokine (see above). The elevated levels of
IFN-a in SLE patients is likely due to the presence of endogenous IFN-a inducers
in the patients. For instance, interferogenic IC in sera have been shown to activate
production of IFN-a in PBMC from normal donors (Vallin et al., 1999a). These
IC consist of autoantibodies and DNA and are termed IFN-a inducing factor in
SLE (SLE-IIF).
The  exact  origin  of  the  non-antibody  part  of  SLE-IIF is  not  known.  The
interferogenic activity of SLE-IIF could be mimicked by combining either SLE-
IgG or anti-dsDNA antibodies with  plasmid  DNA,  which  could  indicate that
microbial  DNA  is  the  actual  IFN-a  inducer  (Vallin et al.,  1999b).  Indeed,
methylation of all CpG in the plasmid abrogated the interferogenic activity, which
indicates a similar mechanism of IFN-a activation by CpG-DNA and SLE-IIF, the
antibody part mediating cell uptake of interferogenic DNA.
The non-antibody part of SLE-IIF could also be derived from dying cells that
release material containing DNA. A possible role of apoptosis in the generation of
SLE-IIF was investigated by Båve et. al., who showed that apoptotic cells in
combination with purified IgG from  SLE-patients could  induce  production of
IFN-a in PBMC  from normal donors (Båve, Alm  &  Rönnblom,  2000). Also
material released from necrotic cells can activate production of IFN-a if combined
with SLE-IgG (T. Lövgren, unpublished observations) In both cases, RNA seems
to be of crucial importance  because interferogenic activity  of  SLE-IgG  was
positively correlated to the presence of antibodies with specificity for RNA-
binding proteins, and the interferogenic activity of the cell derived material was
destroyed by RNase. However, apoptotic cells also released interferogenic material
that was sensitive to Dnase (T. Lövgren, unpublished observations).  Therefore,
DNA and RNA released from dying cells in complex with autoantibodies may be
the actual IFN inducers in SLE. Interestingly, SLE-patients have a wide range of
autoantibodies with specificities for DNA, RNA and associated proteins that may
form such interferogenic IC. Such interferogenic IC are especially prone to occur in21
SLE patients, who have an abnormal a high rate of apoptosis and a  defective
clearance of apoptotic material (Herrmann et al., 1998).
A common property  of  all  SLE-related inducers named  above is  that  they
selectively activate production of IFN-a in NIPC/PDC (Båve et al., 2001; Vallin
et al., 1999a; Vallin et al., 1999b). Moreover, NIPC/PDC  are also activated to
produce IFN-a in response to  poliovirus  in  combination  with  anti-poliovirus
antibodies (Palmer et al., 2000). The presence of antibodies in all these inducers
activating NIPC/PDC  suggests  the  involvement  of  antibody-binding proteins,
such as FcR, in the activation process. Interestingly, it has been demonstrated that
antibodies to FcgRII (CD32) can inhibit the activation of IFN-a production in
PBMC elicited by serum from SLE patients (Batteux et al., 1999).
FcgR on NIPC/PDC
Whereas the NIPC/PDC appear to lack expression of FcgRI (CD64) and FcgRIII
(CD16) (Dzionek et al., 2000; Svensson et al., 1996b), the expression of FcgRII
is  unclear  (Båve et al.,  2001;  Olweus et al.,  1997).  A  low  but  functional
expression can however not  be  excluded, considering the  inhibitory  effect of
antibodies to FcgRII on the IgG-assisted IFN-a production in PBMC (see above).
Also, depletion of cells binding to IgG decreased the IFN-a production induced
by bacteria (Rönnblom, Forsgren & Alm, 1983).
Membrane bound FcR are expressed by the majority of immune cells and enable
them to react to antibodies bound to antigens. The outcome of triggering an FcR
that harbors the immunoreceptor tyrosine-based activation motif (ITAM) in its
cytoplasmic part is cell  activation,  including  antibody-dependent cell-mediated
cytotoxicity, release of cytokines and proteases, as well as clearance of IC  and
phagocytosis of opsonized antigens. Conversely,  activation  of  FcR  with  an
immunoreceptor tyrosine-based inhibition motif (ITIM) will  down-regulate the
immune response, e.g. by  antibody feed-back in  B-cells. In this  way, FcR  are
responsible for many effector functions initiated by humoral immunity, but  also
regulation of the immune response (Ravetch & Bolland, 2001). The FcgRII is in
humans represented by three different genes,  a,  b  and  c  which  in  turn  have
individual isoforms (Zola et al., 2000). FcgRIIa and FcgRIIc are ITAM-bearing
activatory receptors whereas FcgRIIb is an  ITIM-bearing inhibitory  receptor.
Activation of FcR with ITAM results in the phosphorylation of a residue in ITAM
which will activate kinases of the SYK and SRC  families thereby connecting the
transduced signal to common activation pathways, including the MAPK and PI3K
pathway (Daëron, 1997; Takai, 2002). Activation of inhibitory FcgRIIb  induces
phosphorylation of the ITIM that will recruit SH2-domain  containing  proteins
such as SH2 containing inositol  phosphate phosphatase (SHIP) that will  down
regulate cellular activities (Daëron, 1997; Ravetch & Bolland, 2001; Takai, 2002).
These different  properties  of  FcgRIIa/c  and  FcgRIIb  make  it  important  to
determine their presence on NIPC/PDC and possible function in the activation of
IFN-a production in these cells.22
Aims of the study
The present thesis focuses on the activation of IFN-a production by IS-DNA or
interferogenic immune complexes. One reason for this is to better understand the
mechanisms involved in the  activation of  production of  IFN-a, which  is  an
important cytokine in regulation  of  the  immune  response  against  microbial
infections, but also against ‘self’ in autoimmune disorders. Another reason is  to
identify more efficient interferogenic IS-DNA that can be used as adjuvants in
vaccines. The specific aims in this thesis were the following:
® To determine if the vaccine vector pcDNA3 can induce cytokine production in
porcine PBMC and to what extent certain CpG-motifs and the methylation
status of CpG dinucleotides in the plasmid contribute to the IFN-a inducing
ability (Paper I).
® To determine if CpG-ODNs identified in the serum of SLE-patients could
induce production of IFN-a in  human PBMC  from normal donors and to
further examine the structural requirements in  terms of strandness, sequence
and cytosine methylation for the IFN-a inducing ability (Paper II).
® To further examine the interferogenic properties of CpG-containing ODNs in
porcine  PBMC  with  respect  to  the  importance  of  strandness,  sequence,
cytosine  methylation,  phosphorothioate/phosphodiester  composition  and
presence of poly-G sequences (paper III).
® To determine the identity of the human and  porcine PBMC  that  produce
IFN-a in response to IS-DNA, especially if they correspond to the NIPC/PDC
(paper II and III).
® To study the role of FcgR in the IFN-a production induced by interferogenic
immune complexes and to identify the different isoforms of FcgRII  on  the
responding human NIPC/PDC (paper IV).23
Table 1. Inducers used to activate production of IFN-a
Name Type of inducer Comments or Sequence 5’ to 3’ 
1,2
pcDNA3 Plasmid DNA Two AA     CG        TT motifs in ampR gene
Mutant A Plasmid DNA Two AA       GC      TT motifs in ampR gene
Mutant B Plasmid DNA AA     CC      TT and AA       AG        AT in ampR gene
PcDNA3kH Plasmid DNA AmpR gene replaced by kanR gene
pET11c Plasmid DNA Two AA     CG        TT motifs in ampR gene
Poly I:C dsRNA
H ODN TTT TCA ATT      CG        A AGA TGA AT
H
A ODN TTT TCA ATT        AG        A AGA TGA AT
H
GC ODN TTT TCA ATT        GC      A AGA TGA AT
H
met ODN TTT TCA ATT       Me      
5     CG            A AGA TGA AT
H 
G-tail 1 ODN TTT TCA ATT      CG        A AGA TGA ATG GGG G
H 
G-tail 2 ODN GGT TCA ATT      CG        A AGG GGG GG
H 
G-tail 3 ODN GGT TTT CAA TT     C              G        AA GAT GAA TGG GGG G
I ODN ATT CAT CTT      CG        A ATT GAA AA
I
T ODN ATT CAT CTT      CT      A ATT GAA AA
I
GC ODN ATT CAT CTT        GC      A ATT GAA AA
I
met ODN ATT CAT CTT       Me      
5     CG            A ATT GAA AA
I
metx3 ODN ATT       Me      
5     C          AT       Me      
5     C          TT       Me      
5     CG            A ATT GAA AA
RIII ODN ATT GGA AAA      CG        T TCT T     CG         GG
A2 ODN GCT AGA      CG        T TAG      CG        T
A2
GC ODN GCT AGA        GC      T TAG        GC      T
2216 ODN ggG GGA      CG        A T     CG         TCg ggg gG
2216ddiester ODN GGG GGA      CG        A T     CG         TCG GGG GG
D19 ODN ggT GCA T     CG         ATG CAG ggg gg
D19diester (D25) ODN GGT GCA T     CG         ATG CAG GGG GG
MM1 ODN ggG GTC AT     C              G        AT GAg ggg gG
A.pp Bacteria Actinobacillus pleuropneumoniae
HSV Virus Herpes simplex virus
ADV Virus Aujeszky’s disease virus
SV Virus Sendai virus
SLE-IgG+apoptotic cells Interferogenic IC SLE-IgG in combination with apoptotic U937 cells
1  Relevant  CpG  dinucleotides,  the  modified  CpG  dinucleotides  and  methylated
cytosines (Me
5) are underlined.
2  Nucleotides  with  phosphodiester  backbone  are  indicated  with  capital  letters  and
phosphorothioate nucleotides with small letters.24
Results and discussion
DNA sequences that induce IFN-a in human and porcine
PBMC (papers I, II, III)
At the beginning of these studies, plasmid-based DNA vaccines were evaluated in
pigs (Gerdts et al., 1997; Somasundaram et al., 1999; van Rooij et al., 1998),
but little was known about the cytokine inducing capacity of the vectors used. In
human cells, the concept of IS-DNA was established (Pisetsky, 1996), but  there
was incomplete information regarding the characteristics of IS-DNA required to
induce production of IFN-a (see below).  Therefore, nucleotide sequences that
contribute to the interferogenicity of DNA were studied, using plasmid DNA in
porcine PBMC (paper I) or using ODNs in human and porcine PBMC (paper II
and III. The examined inducers are listed in Table 1.
The IFN-a inducing capacity of the plasmid pcDNA3 in porcine PBMC
Early studies in the field of IS-DNA  highlighted  the  DNA  in  the  ampicillin
resistance (ampR) gene as the carrier of immunostimulatory sequences (ISS) of
many DNA vaccine vectors . The presence of two hexameric ISS (5’ AACGTT 3’)
in the ampR were shown to be important for several immunostimulatory effects in
man and mice, including up-regulation of type I IFN and IL-12 mRNA synthesis
in human macrophages (Roman et al., 1997;  Sato et al., 1996). Therefore, the
ability of plasmid DNA to activate cytokine production in pigs  and the relative
importance of the earlier identified ISS in the ampR gene were studied (paper I).
The DNA vaccine vector pcDNA3 was found to  readily induce production of
IFN-a in porcine PBMC,  but only if pre-incubated with lipofectin. Whether pre-
incubated with lipofectin or not,  the plasmid only  induced low  levels of IL-6.
This is contrast to the induction of IL-6 found when porcine cells were stimulated
by CpG-ODN D19 (Kamstrup, Verthelyi & Klinman, 2001),  or  when  murine
spleen cells were exposed to bacterial DNA (Yi et al., 1996). The levels of IFN-a
induced  were  generally  higher  than  those  obtained  with  ADV,  lipofected
Actinobacillus  pleuropneumoniae or lipofected poly I:C. To  evaluate  the
importance of the earlier identified ISS  (5’ AACGTT 3’) on  the  interferogenic
ability of pcDNA3, two mutants were generated by site-directed mutagenesis. In
mutant A both ISS were changed to 5’ AAGCTT 3’ and in mutant B the two ISS
were changed to 5’ AACCTT 3’ and 5’ AAAGAT 3’, respectively. Both mutated
forms of pcDNA3 induced IFN-a production to the same extent as the original
plasmid, or even higher. Thus, the interferogenic activity of pcDNA3 in  porcine
PBMC is not dependent on the earlier identified ISS  (5’ AACGTT 3’) in  the
ampR gene. To determine whether other sequences in the ampR gene were  of
importance, the entire ampR gene was replaced with  the  kanamycin resistance
(kanR) gene, but this did not alter the IFN-a inducing capacity of the plasmid.
Apart from the two  ISS  in  the  ampR  gene,  the  DNA  sequence of  pcDNA3
contains  many  other  potential  immunostimulatory  CpG-motifs,  with  other
flanking bases. To evaluate their overall impact on the interferogenicity of the
plasmid,  all  CpG  dinucleotides  in  the  plasmid  were  methylated  by  SssI25
methylase. This modification totally abolished the IFN-a inducing ability of the
plasmid, demonstrating that unmethylated CpG dinucleotides are crucial for the
activation  of  IFN-a production in porcine PBMC by plasmid  DNA.  Taken
together, other still unknown CpG-motifs must contribute to the IFN-a inducing
capacity of the plasmid pcDNA3. These in vitro results have been confirmed in
vivo using a tissue chamber model where the plasmid pcDNA3 did not affect IL-6
production and induced  production of  IFN-a only  in  the  unmethylated form
(Johansson et al., 2002). Furthermore, plasmid expression was not necessary for
the interferogenic activity  of  plasmid  DNA,  because a  prokaryotic expression
vector induced IFN-a in porcine PBMC to the same extent as pcDNA3. Taken
together, these results show that the induction of IFN-a by plasmid DNA depends
on unmethylated CpG-motifs and that porcine cells may have the same type of
detection system for bacterial DNA as reported for man and mice.
The IFN-a inducing ability of ODN in human and porcine PBMC
(paper II and III)
Experiments with CpG-DNA are often carried out using ssODN to determine the
optimal sequence. Eukaryotic DNA, as well as both bacterial and plasmid DNA,
are  generally  in  the  ds  form,  whereas  viral  DNA  exists  in  both  forms.
Furthermore, eukaryotic ssDNA could occur as a result of apoptosis or necrosis.
Therefore, we tested both ds  and  ss  forms  of  ODNs  when  we  evaluated the
importance of CpG dinucleotides in the IFN-a inducing ability. The initial ODN
sequence studied (designated ODN H) was based on a DNA sequence identified in
the circulation of a patient with SLE (Sato et al., 1999), an autoimmune disease
where IC containing IS-DNA are thought to act as endogenous type I IFN inducers
(Vallin et al.,  1999b).  The  sequence of  ODN H  is  5’-TTTTCAATTCGAA-
GATGAAT 3’ and was chosen because it contains a CpG motif and it had earlier
been shown to induce proliferation and production of IL-12 and IFN-g as well as
up-regulation of MHC  class II and ICAM I expression in  human mononuclear
cells. These activities were dependent on the CpG dinucleotide, because inversion
of the CpG to GpC abolished them (Sato et al., 1999).
Both in human (paper II) and porcine (paper III) PBMC cultures, the ODN H
and its complementary strand ODN I, as well as derivatives of them (see Table 1),
required preincubation with lipofectin in order to induce production of IFN-a. The
importance of lipofectin indicates that cellular uptake of IS-DNA is necessary for
activation of IFN-a production, which is  further discussed below. The optimal
concentrations of lipofectin varied greatly between the two experimental systems.
In general, in human  PBMC  higher  concentrations of  both  components were
required to achieve optimal  induction of IFN-a (50 mg/ml  ODN and 25mg/ml
lipofectin). In the porcine system, titration of ODN and lipofectin revealed that 2.5
mg/ml lipofectin was optimal for all ODN concentrations tested and more than 50
mg/ml ODN did not further increase the ability of ODN to induce  IFN-a. In
general, ODN H, both in ss and ds form, induced 10-20 per cent of the levels of
IFN-a activated by the viral inducer HSV in human PBMC. In contrast, in  the
porcine system, ODN H, and all other CpG-ODNs  tested,  induced similar  or
higher levels than the herpes virus ADV.26
The importance of the CpG dinucleotide in ODN H for IFN-a induction was
evaluated by studying the effect of various alterations of the ODN on its  IFN-a
inducing capacity. Replacement of the cytosine with an adenine in the CpG motif
of ssODN H (H
A), or the guanine with  a  thymine  in  the  CpG  motif  of  the
complementary ssODN I (ODN I
T), severely reduced the induced levels of IFN-a
in human PBMC, and  essentially abolished the induction of IFN-a in  porcine
PBMC. Furthermore, the dsODN H
A-I
T, formed by combining ODN H
A and ODN
I
T, had a severely impaired IFN-a inducing ability  in  both  human and porcine
PBMC  cultures.  Thus,  cytosines  and/or  guanines  are  important  for  the
interferogenic activity of both ss and ds forms of these ODNs in both human and
porcine PBMC.
In the human experimental system, inversion of the CpG dinucleotide to GpC
in ssODN H had no effect, whereas the same modification in ssODN I increased
the interferogenic activity in comparison with the unmodified ODNs. This clearly
shows that the IFN-a inducing capacity in human PBMC  of lipofected ssODN H
or ssODN I is not dependent on the CpG dinucleotide. In the porcine experimental
system,  inversion  of  the  CpG  to  GpC  in  ssODN  H  and  ssODN  I  severely
hampered the IFN-a inducing capacity, but  some  of  the  activity  was  clearly
retained in comparison with the ODN H
A and ODN I
T. However, inversion of CpG
to GpC in the interferogenic CpG-ODN A2 totally abolished the IFN-a inducing
ability in porcine cells. The finding that the GpC-modification had an much more
pronounced effect on the interferogenic ability of ssODN in porcine cells  may
indicate species differences in the recognition of IS-DNA.
The interferogenic activity of ssODN H
GC and ssODN I
GC in human PBMC  was
essentially abolished when these two ODNs were hybridized to form the dsODN
H
GC-I
GC. In the porcine system, dsODN H
GC-I
GC had the same impaired ability to
induce IFN-a as ssODNs with this modification. This illustrates an importance of
CpG dinucleotides for the full interferogenic ability of dsODN H-I in both human
and porcine PBMC.
A major difference between microbial DNA and vertebrate DNA is not only the
frequency of CpG dinucleotides, but also the methylation status of the cytosine in
the CpGs (see the Introduction). The importance of methylation on  the IFN-a
inducing ability of CpG-ODN was examined, using derivatives of ODN H and the
complementary ODN I, where the cytosine in the CpG had been methylated. The
results showed that, the ODN H
met had a reduced ability to  induce  IFN-a in
human  PBMC  compared  to  ODN  H,  whereas  the  potency  of  ODN  I  was
paradoxically strongly increased by methylation. This confirms that the IFN-a
inducing capacity of lipofected ssODN I in human PBMC is not dependent on the
unmethylated  CpG  dinucleotide.  Furthermore,  the  requirement  for  an
unmethylated CpG for the interferogenic ability differs  between  ssODNs.  In
contrast, methylation of the CpG inhibited the IFN-a inducing capacity of both
ssODN H and ssODN I in the porcine system. Again, this indicates  species
differences in the reactivity to ss IS-DNA. When the ODN H
met and ODN I
met were
combined to form dsODN H
met-I
met, the interferogenic ability was clearly reduced
in comparison with the unmodified  dsODN  H-I,  in  both  human  and  porcine27
PBMC. This illustrates the importance of unmethylated CpG dinucleotide for the
interferogenic ability of dsODN H-I in both human and porcine PBMC.
In the human system, combining the inactive ODN H
met with the interferogenic
ODN I
met to dsODN H
met-I
met  resulted  in  a  loss  of  interferogenic  ability  (see
above). This prompted us to investigate whether methylation of the CpG in only
one of the strands in the dsODN H-I was sufficient to  impair the interferogenic
activity in human PBMC. It was found that the hemimethylated dsODN H-I
met,
but not the hemimethylated dsODN H
met-I retained the ability to  induce IFN-a.
The interferogenic activity of dsODN H-I is thus dependent on the unmethylated
CpG in ODN H. The results furthermore revealed that the silencing effect of ODN
H
met was not due to a general inhibitory effect, because the interferogenic ability of
an unrelated ODN (ODN RIII, see Table 1) was not affected (Fig. 3, paper II).
The fact that certain  ssODNs  without  unmethylated CpG  dinucleotides had
potent IFN-a inducing ability in  human PBMC  suggests that eukaryotic DNA
should contain numerous potentially interferogenic sequences. When  cells  die,
either by apoptosis or necrosis, the DNA is fragmented and released, which could
expose the immune system to interferogenic sequences. These findings shed light
on the possible origin of the nucleic acids in  the IFN-a inducer found in  the
serum of SLE-patients, which is discussed below (Results and discussion of paper
IV).
The impact of nucleotide backbone and poly-G sequences on
the interferogenic ability of ODNs in porcine PBMC (paper III)
Phosphorothioate ODNs are often used to increase  nuclease-resistance, which
potentiates and prolongs the adjuvant effects. To evaluate the importance  of
phosphorothioate nucleotides in  interferogenic ODNs, we used earlier identified
interferogenic  ODNs  that  consist  of  a  chimera  of  phosphodiester  and
phosphorothioate nucleotides. The interferogenic activity of these  ODNs  was
compared to ODNs with  the  same  nucleotide sequence, but  with  a  complete
phosphodiester backbone. The chimeric CpG-ODNs 2216 (Krug et al., 2001a) and
D19 (Verthelyi et al., 2001) induced high levels of IFN-a in porcine PBMC in
comparison  with  ADV  and  lipofected  dsODN  H-I.  They  were  furthermore
strikingly independent on preincubation with lipofectin and potent  inducers of
IFN-a  at  low  concentrations  (5mg/ml).  To  evaluate  the  importance  of
phosphorothioate nucleotides in  this  activation, complete phosphodiester ODNs
with the same sequence (2216d and D19d) were synthesized. Also  these ODNs
were potent IFN-a inducers and independent of lipofectin. These results are in line
with the described activation of IFN-a production in human PBMC cultures by
ODN 2216, both as chimera (Krug et al., 2001a) and complete phosphodiester
(unpublished  observation).  Therefore,  the  backbone  composition,
phosphorothioate/-diester chimera vs. complete phosphodiester of these particular
ODNs was not decisive for the IFN-a inducing capacity.
The fact that ODN H  and I,  but  not  2216d and D19d required lipofectin to
induce IFN-a prompted us  to  further investigate the  requirements for  IFN-a
induction. Lipofectin forms cationic liposomes with nucleic acids, which increases28
cellular uptake of ODN (Bennett et al., 1992; Hartmann et al., 1998). The need
for lipofection therefore suggests that cellular uptake of ODN is required for IFN-a
induction, which is in line with  the finding that endocytosis of CpG-ODNs is
required for their immune stimulatory effect (Ahmad-Nejad et al., 2002; Häcker et
al., 1998). The ODNs 2216d and D19d contain a central sequence with  a CpG
motif and flanking poly G-sequences. These poly-G sequences are not present in
the CpG-ODNs ODN  H  or  ODN  I.  Poly  G-sequences may  form  quarternary
structures that facilitate uptake of ODNs, possibly  by  binding  to  scavenger
receptors (Kimura et al., 1994; Lee et al., 2000; Pearson, Rich & Krieger, 1993;
Pisetsky, 1996). This may explain why 2216d and D19d, and not  ODN H  and
ODN I could induce production of IFN-a without preincubation with lipofectin.
To test the effect of poly G-sequences, various numbers of flanking guanines were
added to ODN H (ODNs H
G-tail  1,  H
G-tail  2 and  H
G-tail  3;  see  Table  1)  and  the
modified ODNs were tested for their ability to induce IFN-a production in porcine
PBMC. In the absence of lipofectin, no or very low levels of IFN-a were detected
in  cultures  stimulated  by  ODN  H  or  by  ODN  H  that  contained  additional
guanines.  However,  the  presence  of  poly-G  sequences  strongly  increased,
approximately 1.5 to 5-fold, the IFN-a inducing capacity of lipofected ODN H.
Thus, the addition of poly-G sequences does not seem to eliminate the need for
lipofectin, but increases the levels of IFN-a induced by the ODN.
In conclusion, the exact role  of  phosphorothioate  nucleotides  or  poly  G-
sequences for the interferogenicity of a CpG-ODN is still elusive. The presence of
poly G-sequences nevertheless seemed to  increase the  interferogenic ability  of
CpG-ODNs. Phosphorothioate ODNs have been used as efficient vaccine adjuvants
(Zhang et al., 2003), but are also associated with long-lasting IFN-g and IL-12
production, that can be harmful or even break tolerance (Segal, Chang & Shevach,
2000). The potent interferogenic phosphodiester ODNs that were identified may
therefore be of value as vaccine adjuvants, because they are more short-lived in
vivo and may therefore have fewer side effects.
The identity of the human and porcine cells producing IFN-a in
response to CpG-DNA (paper II and III)
Both human and porcine PBMC produced considerable amounts of type I IFN in
response to CpG-DNA, but the responding cell types were unknown at the start of
the present investigations.  In  human  blood,  there  are  two  major  IPC,  the
monocytes and the NIPC/PDC. In pigs the situation is less clear, but a cell type
that resembles the human NIPC has been identified (Charley & Lavenant, 1990;
Nowacki & Charley, 1993) (see the Introduction). In papers II and III the IPC were
identified by simultaneous flow cytometric (FCM) analysis of the expression of
cell surface markers and intracellular IFN-a in cells stimulated with  CpG-DNA.
The human PBMC responding to CpG-DNA were characterized using antibodies
previously employed to phenotype the NIPC/PDC (Olweus et al., 1997; Rissoan
et al., 1999; Svensson et al., 1996b). The porcine PBMC  producing IFN-a in
response to CpG-DNA were phenotyped using antibodies reactive to specific
lineage markers and  markers used  in  the  earlier phenotyping  of  porcine IPC
activated by TGEV (Nowacki & Charley, 1993; Riffault et al., 1997; Riffault et29
al., 2001). Furthermore, the porcine cells expressing IFN-a mRNA were detected
by in situ hybridization (ISH), using a biotinylated poIFN-a cRNA probe and a
sensitive catalyzed amplification system.
Human PBMC were stimulated with CpG-DNA in the form of lipofected
ssODN H or lipofected dsODN H-I, using HSV as a control (paper II). Porcine
PBMC were stimulated with CpG-DNA in the form of ODN 2216 or lipofected
pcDNA3, using ADV as a control (paper III). The results demonstrate that the
human IPC did not express CD19 and the porcine IPC did not express CD21, and
none of them expressed CD3. This indicates that these IPC are not B- or T-cells.
Both the porcine and human IPC studied here expressed MHC class II and CD4,
although the human IPC had a weak CD4 expression compared to that on  other
human PBMC (Fig. 4 paper II). Porcine IPC  expressed high  levels  of  CD4,
comparable to the brightest CD4+ populations of porcine PBMC  (Fig.  7  paper
III). CD4 is a marker present on  many cell types,  including Th  cells, DC  and
monocytes. Neither porcine nor human IPC expressed CD14,  which shows that
they are not monocytes. Taken together, the human and porcine IPC responding to
CpG-DNA phenotypically clearly resembles each other.
Further analysis of the human IPC stimulated by CpG-DNA revealed that they
also expressed CD40, CD83, IL-3R and CD36, but not CD11c (paper II), which
shows that they are identical to the earlier described human NIPC/PDC (Siegal et
al., 1999; Svensson et al., 1996b). In paper IV, expression of FcgRII on human
NIPC/PDC was also demonstrated. FcgRIIIA has been demonstrated on  porcine
cells (Sweeney, Halloran & Kim, 1996), including myeloid DC (Carrasco et al.,
2001), but the expression of this and other FcgR on  porcine IPC  has not  been
reported. Given the pivotal role of FcgRIIa in the activation of human NIPC/PDC
(see Introduction and paper IV), it is of great interest to examine the expression
and function of this FcR on porcine IPC. Interestingly, early studies on  porcine
leukocytes indicated that ability to produce IFN  correlated with  expression of
FcRs (Salmon et al., 1989).
Analysis of the porcine IPC responding to CpG-DNA furthermore showed that
they expressed intermediate levels of SWC3 (Fig. 7 paper  III).  The  SWC3
molecule is a 90-115 kDa protein whose function is unknown, although it exhibits
homology to members of the family of signal regulatory proteins (Alvarez et al.,
2000). The expression of SWC3 on porcine IPC is  in  agreement with  earlier
studies using TGEV as inducer (Riffault et al., 1997;  Riffault et  al., 2001).
TGEV-activated  porcine  IPC  were  recently  thoroughly  characterized  by
Summerfield and colleagues (A. Summerfield,  personal communication). They
observed that porcine PBMC producing IFN-a in  response to  TGEV  had  an
intermediate expression of SWC3 and MHC class II and a strong expression of
CD4. The TGEV-activated IPC lacked the monocytic marker CD14 and markers
for T- and B-cells. Therefore, the porcine PBMC  producing IFN-a in response to
CpG-DNA phenotypically resemble the IPC activated by TGEV.
The porcine IPC responding to CpG-DNA also expressed CD2, which has not
been reported for porcine IPC before. Seemingly in contrast with this  are earlier
studies, where depletion of CD2+ cells did not hamper the ability  of  porcine
PBMC to produce IFN-a in response to TGEV (Nowacki & Charley, 1993). The30
reason for this discrepancy is not  known. The CD2  expression by  porcine IPC
responding to CpG-DNA is however in agreement with the expression of CD2 on
human NIPC/PDC (Comeau et al., 2002). The CD2  molecule is  expressed by
many different cell types including porcine T- and NK-cells (Yang & Parkhouse,
1996),  but  also  on  porcine  thymic  DC  (Salmon et  al.,  2000)  and  human
monocyte-derived DC (Di Pucchio et al., 2003).
The hematopoietic origin of human NIPC/PDC has been debated (Brière et al.,
2002). Recent work has shown that NIPC/PDC,  but  not  monocyte-derived DC
expressed  immunoglobulin-like  transcripts  (Rissoan et al., 2002), which is
indicative of a lymphoid origin of NIPC/PDC. This is now a fairly accepted view,
but it has also been suggested that NIPC/PDC can convert to a myeloid phenotype
(Comeau et al., 2002). The porcine surface molecule SWC3 is regarded as a pan-
myeloid marker (Summerfield & McCullough, 1997) that is present on 80-90 per
cent of monocytes and  granulocytes, but  also  on  5  per  cent  of  lymphocytes
(Thacker et al., 2001). Therefore, the expression of SWC3 on porcine IPC  does
not permit a clear assignment of the cells as myeloid or lymphoid. However, the
porcine IPC activated by CpG-DNA are  not  likely  monocytic  DC,  because
monocytes or monocyte-derived porcine DC failed to produce IFN-a in response
to CpG-DNA and ADV (Johansson et al., 2003). The porcine monocyte-derived
DC could however produce IFN-a in response to SV. This is reminiscent of the
situation in human blood, where monocytes produce IFN-a in  response to  SV,
but not in response to CpG-DNA (Fitzgerald-Bocarsly, 2002).
The human NIPC responding to CpG-ODN constituted approximately 0.1  per
cent of  total  PBMC,  as  determined by  FCM,  which  is  in  line  with  earlier
estimations of this population (Svensson et al., 1996b). The frequency of IPC
detected by in situ hybridization in porcine PBMC was ≤ 0.1 per cent, when CpG-
ODN, lipofected plasmid DNA or ADV were used as inducers. All  IPC  were
strongly  labelled  suggesting  a  uniformly  high  content  of  IFN-a mRNA.
Estimation of the frequency of IPC by FCM revealed that among porcine PBMC
activated by CpG-ODN or lipofected plasmid, up to 0.3 per cent were stained by
anti-IFN-a antibodies. In contrast, approximately ten-fold lower frequencies were
obtained by this method when PBMC were activated with ADV. In general, ADV
induced much lower levels of IFN-a than CpG-DNA, which may reflect the lower
numbers of cells activated (paper III). This low frequency of virus-activated IPC is
in line with  the frequency of IPC  activated in  porcine PBMC  stimulated with
TGEV (1 per 10
4 PBMC) (Nowacki &  Charley, 1993) and also with  that of a
recent study of the phenotype of TGEV-activated IPC (A. Summerfield, personal
communication). This suggests that CpG-DNA is a stronger activator of porcine
NIPC than virus.
In summary, the characterization of IPC has revealed that the earlier described
NIPC/PDC are the only human cell type in PBMC  producing IFN-a in response
to CpG-DNA. This is line with other recent studies (Krug et al., 2001a; Krug et
al., 2001b) using phosphodiester/phosphorothioate chimeric CpG-ODNs that do
not require lipofectin for activity. Our data showed that the same NIPC/PDC are
also selectively activated by lipofected CpG-containing phosphodiester ODNs, that
by themselves are inactive. The porcine blood cells producing IFN-a in response31
to phosphodiester/phosphorothioate chimeric CpG-ODN or  lipofected  plasmid
DNA resembles the human NIPC/PDC and may therefore constitute the porcine
counterpart to this infrequent but highly efficient IPC, identified in both man and
mice. It appears that the NIPC/PDC  in  both  man and pigs  are unique in  their
ability to produce IFN-a in response to DNA, provided that the DNA is taken up
by cells and/or that certain signals are delivered to the NIPC/PDC. This necessary
assistance can be provided to the NIPC/PDC  by  lipofectin or  antibodies  (see
below).
The mechanism of IFN-a induction in human NIPC/PDC by
interferogenic immune complexes (paper IV)
The interferogenic IC in SLE serum, commonly referred to as SLE-IIF, models of
these  IC,  or  poliovirus  in  combination  with  anti-poliovirus  antibodies  all
selectively activate production of IFN-a in NIPC/PDC (see the Introduction). The
requirement for IgG-assisted activation prompted us to further investigate the role
of SLE-IgG and FcgR on NIPC/PDC in the activation of IFN-a production.
First, we investigated the importance of the Fc-part of SLE-IgG in the activation
of IFN-a production in  cultures of human PBMC  by  apoptotic U937 cells in
combination with SLE-IgG. The SLE-IgG was pretreated with papain or pepsin to
generate Fab fragments or F(ab’)2 fragments, respectively. The  combination  of
apoptotic cells and intact SLE-IgG, but not Fab or F(ab’)2 fragments of SLE-IgG,
induced  IFN-a production, which  suggests  that  the  Fc-part  of  SLE-IgG  is
important in this activation.
Aggregated IgG is known to bind to and block even low affinity FcR. To test if
aggregated IgG could inhibit IFN-a production in  PBMC,  untreated or  heat-
aggregated normal IgG was added to the PBMC  cultures. It was found that such
IgG, especially in the heat-aggregated form, severely hampered the interferogenic
activity of SLE-IgG in combination with apoptotic cells. This suggests that FcgR
binding by other IgG molecules can inhibit the activation of IFN-a production by
interferogenic IC. Interestingly, also the IFN-a production induced by CpG-ODN
2216 and HSV was inhibited by aggregated IgG, suggesting that FcR-binding can
inhibit the IFN-a production stimulated by principally different IFN-a inducers
that are not know to depend on FcR for induction.  The  aggregated IgG  may
therefore generally down-regulate production of IFN-a in NIPC/PDC .
To determine if any particular types of FcgR were involved in the activation of
IFN-a by the combination of SLE-IgG and apoptotic cells, we added antibodies
that recognize and block FcgRI (CD64), FcgRII (CD32) or FcgRIII (CD16) to the
PBMC cultures. The  interferogenic activity  of  SLE-IgG in  combination  with
apoptotic cells was efficiently inhibited by  the anti-FcgRII mAb,  whereas anti-
FcgRI or anti-FcgRIII mAb  hade no  inhibiting  effect. F(ab) fragments of anti-
FcgRII mAb were sufficient to block the activation, which suggests that cross-
linking of the FcR or the Fc-portion of the mAb was not necessary to achieve the
inhibition. The monoclonal antibody (IV:3) used to inhibit the IFN-a production
recognizes FcgRIIa, but  probably not  FcgRIIc  (Metes et  al., 1998)  and  not
FcgRIIb (Van Den Herik-Oudijk et al., 1994). This suggests the involvement of32
especially the FcgRIIa in the activation of IFN-a by the combination of SLE-IgG
and apoptotic cells. In contrast, the induction of IFN-a induced by HSV or 2216
was not affected by the mAb IV:3, indicating that they are not  using  FcgR  to
induce IFN-a. However, the anti-FcgRII mAb AT:10 that recognizes all  three
isoforms  FcgRIIa/b/c,  strongly  inhibited  the  IFN-a induction by all  three
inducers. This suggests that the mAb AT:10 acted in a similar way as aggregated
IgG, causing a general inhibition of the  production of  IFN-a in  NIPC/PDC,
possibly by activating the inhibitory FcgRIIb.
The  involvement  of  a  FcgRII  in  the  activation  or  inhibition  of  IFN-a
production suggested that the responding cells should express this receptor. Earlier
studies on the expression of FcgRII on NIPC/PDC have not been conclusive (see
the  Introduction).  Therefore,  our  findings  prompted  us  to  reinvestigate  the
expression of FcgRII on NIPC/PDC. This was done by simultaneous staining of
fresh PBMC for FcgRII  using  the mAb  FLI8.26  that recognize FcgRIIa,  b,  c
combined with staining for the specific NIPC/PDC  marker BDCA-2. We could
demonstrate that the NIPC/PDC constituted about 0.5 per cent of PBMC, and that
approximately 50 per cent of NIPC/PDC expressed intermediate levels of FcgRII.
Because only a subpopulation of  NIPC/PDC  expressed FcgRII,  we  examined
whether the actual cells producing IFN-a expressed FcgRII. To this end, PBMC
were stimulated with HSV, an inducer not known to engage this receptor, and then
simultaneously  stained  for  FcgRII (mAb  FLI8.26  or  IV:3)  and  intracellular
IFN-a. A clear but low expression of FcgRII  was seen on  essentially all  IPC,
which demonstrates that NIPC/PDC in fact are capable  of  expressing FcgRII.
Because  all  actual  IPC  expressed  FcgRII,  the  NIPC  may  constitute  a
subpopulation  of  the  BDCA-2-defined  PDC,  possibly  defined  by  FcgRII
expression. In accordance, it has been shown that only 10-50  per  cent  of  the
BDCA-2+ cells are capable of producing IFN-a in response to HSV (Blomberg et
al., 2003).
The expression of the three different isoforms FcgRIIa/b/c on NIPC/PDC  was
further analyzed by  RT-PCR.  A  cell population enriched for BDCA-4 positive
NIPC/PDC was first generated from a pool  of PBMC  by  magnetic separation.
These cells were further purified by fluorescent activated cell sorting (FACS) for
BDCA-2 positive cells, resulting in  almost  100  per cent pure BDCA-2+ cells.
Messenger RNA prepared from these cells or from  unsorted  PBMC  was  then
reverse transcribed to cDNA. Measurement of the three different FcgRII transcripts
by PCR showed that  cDNA from unsorted PBMC  contained transcripts for all
three isoforms, whereas cDNA from the BDCA-2+ cells only  contained  the
FcgRIIa transcript. Consequently, NIPC/PDC appear to selectively express  the
FcgRIIa, but not other FcgRs.
The unique expression of FcgRIIa on NIPC/PDC and the inhibitory effect of the
mAb  IV:3  suggest  that  FcgRIIa  is  involved  of  in  the  activation  of  IFN-a
production induced by the  combination  of  SLE-IgG and  apoptotic  cells.  The
absence of the inhibitory FcgRIIb on NIPC/PDC furthermore suggests that this
FcgRII is not involved in the general inhibition of IFN-a production by the mAb
AT:10 or heat-aggregated IgG. Instead the activatory FcgRIIa may under certain
circumstances be inhibitory. In fact, it has recently been shown that the ITAM of33
FcgRIIa can also activate the phosphatase SHIP (Huang et al., 2003; Nakamura,
Malykhin  &  Coggeshall,  2002),  which  can  inhibit  various  types  of  cellular
activation pathways e.g.  NFkB-induced gene transcription (Tridandapani et al.,
2002). Therefore, strong activation of FcgRIIa by aggregated IgG or the pan anti-
FcgRII mAb AT:10 may cause activation of SHIP that mediates down-regulation
of IFN-a production in NIPC/PDC.
The active components in the interferogenic IC are possibly DNA or RNA, as
demonstrated  by  DNAse  (Vallin et  al.,  1999a)  or  RNAse  (T. Lövgren,
unpublished observations) treatment. The  antibodies  in  interferogenic IC  may
trigger FcgRIIa-mediated phagocytosis, followed by intracellular recognition of
immunostimulatory nucleic acids. Such activation may be conferred by TLR9 that
binds CpG-DNA at the  inside  of  intracellular vescicles (Ahmad-Nejad et  al.,
2002), or possibly by other TLRs present in NIPC/PDC. The signalling pathways
from FcgRIIa may also be important in  the eventual activation of IFN-a gene
expression induced by interferogenic IC (see the Introduction).
The  FcgRIIa  on  NIPC/PDC  probably  has  a  more  general  function  than
mediating activation by the special IC in autoimmune diseases, such as SLE.  It
may participate in the activation of NIPC/PDC  by  IC  formed by  Ig and virus
(Palmer et al., 2000) and perhaps other microorganisms. Viral infection may also
activate formation of autoantibodies (Hunziker et al., 2003) that can react with
material from dying cells. Tissue damage and concomitant release of apoptotic or
necrotic material, as  a  result  of  e.g.  viral  infection,  may  in  the  presence of
autoantibodies give rise to interferogenic IC that can activate production of IFN-a
in  NICP/PDC.  Therefore,  the  NIPC/PDC  have  the  ability  to  react  to  both
exogenous danger signals from microorganisms, and endogenous danger signals
from damaged tissues (Gallucci & Matzinger, 2001). The acute phase reactants C-
reactive protein and serum amyloid P that can opsonize microbes and apoptotic
cells (Mold, Baca & Du Clos, 2002), and bind DNA (Pepys & Butler, 1987) or
ribonucleoproteins (Du Clos, 1989), have also been showed to bind to and activate
FcgRIIa (Bharadwaj et al., 2001; Chi et al., 2002). This suggests the existence of
other complexes that can activate NIPC/PDC via FcgRIIa.34
General summary and conclusions
The aim of this thesis was to study the activation of type I IFN production by
inducers containing nucleic acids in  human and porcine blood  cells. The main
findings and conclusions were:
® Immunostimulatory DNA in the form of the DNA vaccine vector pcDNA3
can  activate  production  of  IFN-a in  porcine  PBMC.  The  in  vitro
stimulatory capacity probably required uptake  of  the  pcDNA3 by  cells,
because pretreatment of the plasmid with  the transfecting agent lipofectin
was necessary for  activation  of  IFN-a production.  The  plasmid  only
induced low levels of IL-6, regardless of lipofection. Unmethylated CpG
motifs were a prerequisite for activation of IFN-a production, because
specific  methylation  of  CG  sequences  abolished  the  IFN-a inducing
capacity of the plasmid. However, the earlier defined two ISS (5’AACGTT
3’) in the ampR gene were not essential for the IFN-a inducing ability of
the  plasmid,  indicating  that  other  CpG-motifs  in  the  plasmid  must
contribute. Expression of  the  plasmid  was  not  necessary for  induction,
which indicates that it is the DNA that harbors  the  immunostimulatory
activity and not RNA or protein expressed by  the plasmid.  These results
show  that  the  induction  of  IFN-a  by  plasmid  DNA  depends  on
unmethylated CpG-motifs and that porcine cells may have the same type of
detection system for bacterial DNA as reported for man and mice.
® The activation of IFN-a by IS-DNA was further investigated in  human
PBMC using ODNs derived from DNA sequences identified in the serum of
SLE patients (ODN H: 5’ TTTTCAATTCGAAGATGAAT 3’) in ss or ds
form.  Cellular  entry  of  DNA  was  probably  a  requirement,  because
pretreatment of ODNs with lipofectin was necessary for activation of IFN-a
production. The importance of the CpG dinucleotide in ODN H  and  its
complementary  strand  ODN  I  for  IFN-a induction  was  evaluated  by
studying the effect of various alterations of the ODN on its IFN-a inducing
capacity. It was found that certain ss forms of ODN H could induce IFN-a
in human blood cells in the absence of unmethylated CpG  dinucleotides,
which contradicts the widely held concept of  unmethylated CpGs  being
necessary for cytokine activation by DNA. However, in the ds form, an
unmethylated CpG was necessary for full activity, indicating differences in
the recognition of ss and dsDNA.  Because unmethylated CpG  was  not
always required for the interferogenic activity, many  immunostimulatory
DNA sequences should be present in eukaryotic DNA, and  not  only  in
prokaryotic DNA. Such eukaryotic DNA sequences might be  formed by
decomposing genomes of dying cells and constitute potential endogenous
IFN-a  inducers.  They  may  become  active  when  complexed  with
autoantibodies, as in SLE.35
® In porcine PBMC,  the full  interferogenic activity of ss  and ds  forms of
ODN H required lipofectin and unmethylated CpGs. Certain CpG-ODNs
with flanking poly G-sequences (e.g. ODN 2216 and ODN 2216d) were
potent inducers of IFN-a production in the absence of lipofectin, both  as
phosphorothioate/phosphodiester chimeras or  as  phosphodiesters.  Such
phosphodiester ODNs may  be  particularly useful  as  immunostimulatory
adjuvants. The poly-G sequences may enhance the interferogenic ability of
ODNs by facilitating their uptake by cells, but may also act in other ways.
For instance, it was found that addition of poly-G sequences to  ODN H
enhanced its IFN-a inducing ability, but did not eliminate the need for
lipofectin. The mode of action of poly-G sequences therefore merits further
study.
® The NIPC/PDC were the only cells among human PBMC producing IFN-a
in response to lipofected ssODN H or dsODN H-I. This was shown by flow
cytometry, using simultaneous detection  of  intracellular IFN-a and  cell
surface markers. The same  approach revealed that  the  porcine  PBMC
producing IFN-a in response to ODN 2216 or lipofected pcDNA3 expressed
MHC class II, CD2, CD4 and SWC3 but not markers for T-cells, B-cells or
monocytes. These IPC constituted 1-3 cells per 1000 PBMC  and this low
frequency was confirmed by in situ hybridization, detecting cells containing
poIFN-a  mRNA.  The  principal  porcine  IPC  activated  by  CpG-DNA
therefore appear to be the NIPC/PDC  and correspond to  earlier identified
virus-activated porcine IPC.
® The human NIPC/PDC are also activated to  produce IFN-a by  apoptotic
cells  in  combination  with  IgG  autoantibodies  from  SLE  patients.  The
involvement of FcgRII in this activation, but not FcgRI or FcgRIII,  was
demonstrated using mAbs blocking these receptors. The mAb IV:3, which
may preferentially block FcgRIIa, inhibited production of IFN-a induced
by SLE-IgG in combination with apoptotic cells, but not that induced by
HSV or ODN 2216. The responding NIPC/PDC had a significant but weak
expression  of  FcgRII  as  determined  by  flow  cytometry,  and  purified
BDCA-2  positive  NIPC/PDC  were  by  RT-PCR  shown  to  express  the
isoform FcgRIIa, but not FcgRIIb or FcgRIIc. While FcgRIIa can mediate
the activation of IFN-a production in  NIPC/PDC  by  interferogenic IC,
FcgRIIa may also convey inhibitory signals. This can explain the general
inhibitory  effect  of  heat-aggregated  IgG  on  the  IFN-a  production  in
NIPC/PDC induced by interferogenic IC, HSV or ODN 2216.
The human and porcine NIPC/PDC may be pivotal cells in  the activation of
type I IFN production by exogenous and endogenous inducers containing nucleic
acids, e.g. CpG-DNA or interferogenic IC containing  DNA  and/or  RNA.  The
NIPC/PDC can for instance recognize CpG-DNA by means of TLR9,  but  other
mechanisms may be involved in their activation by RNA and  other  forms  of
DNA. Furthermore, certain molecules on NIPC/PDC may be important, such as
scavenger receptors that can interact with poly-G sequences and FcgRIIa that can36
interact with antibodies in IC. They may like lipofectin facilitate uptake of the
IFN-a inducers or provide accessory signals that are necessary for the activation of
the  NIPC/PDC.  It  is  important  to  further  clarify  the  mechanisms  whereby
NIPC/PDC are activated, because this  can allow development of more efficient
adjuvants for use in vaccines, and also provide targets for new therapies aiming at
inhibition of the pathologic activation of NIPC/PDC in autoimmune  diseases,
such as SLE.37
Figure 1. Selective surface molecules expressed by human and/or  porcine  NIPC/PDC
and  cytokines  produced  by  the  cells  in  response  to  exogenous  and  endogenous
inducers. Exogenous IFN-a inducers include virus and bacteria and their products such
as CpG-DNA. Endogenous IFN-a inducers  include  immune complexes  (IC) containing
IgG and nucleic acids (RNA or DNA). Anti-virus antibodies  and  virus  can  also  form
interferogenic IC. The inducers may also trigger  production  of other cytokines  (IL-12,
chemokines, etc.). The figure is based on published  findings  and results  presented  in
this  thesis.38
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